Laureate Pharma Announces Development & Manufacturing Agreement With ZZ Biotech
Laureate Pharma, Inc. Logo. (PRNewsFoto/Laureate Pharma, Inc.)
PRINCETON, NJ UNITED STATES
- Laureate to Manufacture ZZ Biotech's Novel Product Candidate -
PRINCETON, N.J., Sept. 24 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a development and manufacturing agreement with ZZ Biotech, LLC. According to the agreement, Laureate will produce Activated Protein C variant under cGMP conditions. Terms of the manufacturing agreement were not disclosed.
"We are pleased that ZZ Biotech has chosen Laureate as their manufacturing partner," said Robert J. Broeze, Ph. D., President & CEO of Laureate. "We will work closely with the ZZ Biotech team and help them drive their product from development into the clinic."
"Laureate Pharma has a proven track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-scale grade materials," said Berislav V. Zlokovic, M.D., Ph.D. Founder and Chief Scientific Officer of ZZ Biotech, Dean's Professor and Director Center for Neurodegenerative and Vascular Brain Disorders at the University of Rochester, NY. "This agreement enables us to operationally leverage Laureate's expertise and infrastructure while we seek to establish new treatment for stroke and neurodegenerative disorders."
About Laureate Pharma
Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, NJ. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Dan Leone, Vice President, Business Development at 609-
ZZ Biotech is a company with a mission to develop new therapies for the aging and damaged brain, including those affected by stroke and other neurodegenerative disorders. ZZ Biotech R & D Laboratories are located at the BioVenture Center at the University of Rochester, NY. Activated Protein C (APC) variant is a recombinant protease with reduced anticoagulant activity and preserved cytoprotective activities. This APC variant protects brain cells from ischemic injury and different forms of neurodegeneration. For more information, contact Joseph Romano, Chief Financial Officer at jromano@zilkha.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
